The Animal Vaccines Industry Is Expected To Surpass A CAGR Of 9.2% From 2022-2032

Coloured Lenses Market

Fact.MR states the global sales of animal vaccines are expected to surpass US$ 29 Bn by registering a positive CAGR of 9.2% in the forecast period 2022-2032. Food and clothing industry largely depends on animals for milk, meat and wool. Thus, animal safety has become important. Moreover, increase in canine disorders are a major concern in animals. To avoid the same, the demand for animal vaccines has increased.

Historically, from 2015 to 2021, the global sales of animal vaccines expanded at a CAGR of 8.6%, closing at a value of US$ 11 Bn. The COVID-19 pandemic further reinforced the need to increase production of animal vaccines, amid the fear of contracting the virus from animals. Thus, governments of various countries focused on vaccinating animals. This, in turn, is increasing the sales of animal vaccines.

Furthermore, increasing investment in research and development by key players is positively influencing the demand for animal vaccines. In addition, rapidly growing livestock population is fueling the growth of animal vaccines. Thus, the aforementioned factors are expected to boost the sales of animal vaccines.

Get Sample Copy With Impact Analysis Of COVID-19 Of Market Report –

Key Takeaways from the Market Study

  • By product, attenuated live vaccines expected to hold more than 30% market share for animal vaccines.
  • Livestock expected to hold more than 65% market share for animal vaccines
  • North America expected to hold more than 23% market share for animal vaccines.
  • Asia Pacific expected to possess more than 20% market share for animal vaccines.
  • Global animal vaccines market demand to be valued US$ 12 Bn by the end of 2022

“Frequent episodes of outbreaks of zoonotic diseases and their transmission to humans has highlighted the importance of maintaining animal health. This has widened expansion prospects for animal vaccines, prompting animal health specialists to conduct various clinical trials of multiple vaccine formulations,” states a Fact.MR analyst.

How do Animal Vaccines Growth Prospects appear in North America?

Canine Disorders Driving Demand for Animal Vaccines in North America

The increasing presence of well-established pharmaceutical are striving for wide commercialization of their vaccines and propelling their geographical reach in countries like U.S. and Canada is expected to bolster the market growth. Moreover, high prevalence of livestock and zoonotic diseases leading to large-scale animal deaths is a major concern in the region.

In addition, the rising incidence of canine disorders along with a surge in the increasing adoption of vaccination is driving the demand for animal vaccines. Also, the rising pet population in the U.S. is a major factor contributing to the expansion of the regional market. Thus, North America is expected to hold more than 23% market share for animal vaccines.

Which Vaccine Type is expected to Accrue Maximum Market Gains?

Reduction in Mortality Rate Creating Lucrative Opportunities for Attenuated Live Vaccines

Live attenuation is not only the oldest vaccination method used in the veterinary field but now is also being used under trial for the development of additional applications. Some alternatives include the development of protein subunit vaccines for swine as they are given intramuscularly.

Thus, these products help in reducing the mortality rate by improving the life span of disease-affected swine. By product, attenuated live vaccines are expected to hold more than 30% market share for animal vaccines.

Speak To Research Analyst For Detailed Insights:

Competitive Landscape

Prominent manufacturers of animal vaccines are capitalizing on increasing government support across countries to promote animal health. This support is translating into the introduction of robust vaccine formulations against a wide variety of pathogen. Moreover, players are emphasizing on mergers, acquisitions and collaborations to secure firm footing in this highly competitive environment. Some notable developments are as follows:

In August 2020, Merck & Co., Inc. completed the acquisition of IdentiGEN. The company is focusing on studying DNA of animals for livestock. Through this acquisition, Merck intends to provide complete transparency to food processors, producers and retailers, regarding animal traceability solutions to ensure that good quality food is available to consumers

In January 2022, Zoetis Inc. announced that the U.S Food and Drug Administration has approved SolensiaTM (frunevetmab injection) to control the pain of osteoarthritis in cats, helping improve their mobility, comfort and overall well-being. The injection works by directly targeting the Nerve Growth Factor (NGF), a key OA pain driver

Key Segments Covered in the Animal Vaccines Industry Report

By Product

  • Attenuated Live Animal Vaccines
  • Recombinant Animal Vaccines
  • DNA Animal Vaccines
  • Inactivated Animal Vaccines
  • Subunit Animal Vaccines

By Animal Type

  • Livestock Animal Vaccines
  • Poultry
  • Ruminants
  • Swine
  • Aqua
  • Companion Animal Vaccines
  • Canine
  • Feline
  • Others

By Route of Administration

  • Subcutaneous Administration of Animal Vaccines
  • Intranasal Administration of Animal Vaccines
  • Intramuscular Administration of Animal Vaccines

For in-depth competitive analysis, Buy Now –

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.


US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Visit Our Website:



Leave a Reply

Your email address will not be published. Required fields are marked *